RxDoctor Payments Data

Carlos Campos

Family Medicine · New Braunfels, TXNPI 1376730747

Payments from drug & device makers

$1,479,466in general payments, 2019–2025

Across 2,939 payments — averaging $503.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$754K
  • Novo Nordisk$522K
  • Boehringer Ingelheim$65K
  • Eli Lilly$55K
  • Johnson & Johnson$54K
  • Janssen Scientific Affairs, LLC$6K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$221,33915%
  • Speaking & faculty fees$956,54865%
  • Travel & lodging$260,55918%
  • Food & beverage$40,7073%
  • Education$3120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC1,326$753,537
Novo Nordisk570$521,578
Boehringer Ingelheim130$65,111
Eli Lilly85$55,144
Johnson & Johnson101$54,323
Janssen Scientific Affairs, LLC9$5,652
Astellas Pharma US Inc8$4,949
AstraZeneca34$4,304
Abbott15$2,528
AbbVie(2 entities)180$2,522
Esperion Therapeutics, Inc.7$1,103
Corcept Therapeutics75$1,076
Mannkind Corporation49$839
Bayer40$704
Amarin Pharma, Inc.34$483
Amgen(2 entities)26$442
Otsuka America Pharmaceutical, Inc.24$436
Pfizer22$399
Takeda Pharmaceuticals U.S.A., Inc.24$392
Bausch Health US, LLC19$346
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$340
Medtronic4$311
GSK16$283
Nevro Corp.6$191
Novartis8$182
Axsome Therapeutics, Inc.7$151
Dexcom, Inc.7$145
Sanofi-aventis U.S. LLC5$144
Intuitive Surgical1$135
Phathom Pharmaceuticals, Inc.1$113
Madrigal Pharmaceuticals1$98
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$97
Ascensia Diabetes Care US Inc.6$95
Azurity Pharmaceuticals, Inc.5$94
Exact Sciences4$87
Xeris Pharmaceuticals, Inc.4$84
Merck6$83
Insulet Corporation4$81
Cequr Corporation3$75
Recordati_rare_diseases_inc.4$75
Shield Therapeutics Inc4$71
Currax Pharmaceuticals LLC4$63
Vertex2$59
Globus Medical2$56
Echosens North America, Inc.1$40
Neurocrine Biosciences, Inc.2$40
Paratek Pharmaceuticals, Inc.2$40
Kowa Pharmaceuticals America, Inc.3$39
Painteq LLC2$36
Genentech, Inc.1$29
Soleno Therapeutics, Inc.1$29
Idorsia Pharmaceuticals US Inc2$27
BETA Bionics, Inc.1$25
Intra-sana Laboratories1$24
Valeritas, Inc.2$23
Teva Pharmaceuticals USA, Inc.1$21
Averitas Pharma Inc.1$21
Lundbeck LLC1$17
Amneal Pharmaceuticals LLC1$17
Supernus Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,479,466 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$156,840
Medicare patients
490
Services billed
2,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide130$154,526
JardianceEmpagliflozin143$150,661
OzempicSemaglutide91$105,166
TrulicityDulaglutide46$54,643
Synjardy XrEmpagliflozin/Metformin Hcl62$48,551
FarxigaDapagliflozin Propanediol54$40,261
Xigduo XrDapaglifloz Propaned/Metformin39$35,993
SynjardyEmpagliflozin/Metformin Hcl31$18,198
Tresiba Flextouch U-200Insulin Degludec25$17,234
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$11,781
EliquisApixaban12$6,437
PremarinEstrogens, Conjugated11$6,216
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$5,035
SynthroidLevothyroxine Sodium45$4,537
Levothyroxine Sodium275$3,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$65,111$217,410236 claims
Lilly USA, LLCMounjaro, Trulicity$753,537$209,169176 claims
Novo NordiskOzempic$521,578$105,16691 claims
AstraZenecaFarxiga$4,304$40,26154 claims
PfizerEliquis, Premarin$399$12,65223 claims
AbbVieSynthroid$2,522$4,53745 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$3,082275 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →